KORU Medical Systems (NASDAQ:KRMD) CTO Eric Schiller Buys 5,000 Shares of Stock

KORU Medical Systems, Inc. (NASDAQ:KRMD) CTO Eric Schiller bought 5,000 shares of the business’s stock in a transaction on Monday, May 18th. The shares were acquired at an average cost of $3.91 per share, for a total transaction of $19,550.00. Following the purchase, the chief technology officer directly owned 5,000 shares in the company, valued at $19,550. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

KORU Medical Systems Trading Up 1.0%

Shares of KRMD stock opened at $4.00 on Thursday. KORU Medical Systems, Inc. has a 1-year low of $2.63 and a 1-year high of $6.61. The company has a market capitalization of $183.72 million, a price-to-earnings ratio of -80.00 and a beta of 0.43. The stock’s fifty day simple moving average is $4.19 and its 200-day simple moving average is $4.84.

KORU Medical Systems (NASDAQ:KRMD) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.02). KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%.The firm had revenue of $11.76 million during the quarter, compared to analysts’ expectations of $11.28 million. On average, sell-side analysts predict that KORU Medical Systems, Inc. will post -0.04 EPS for the current year.

Hedge Funds Weigh In On KORU Medical Systems

Several hedge funds have recently modified their holdings of KRMD. Cubist Systematic Strategies LLC grew its holdings in shares of KORU Medical Systems by 927.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 77,280 shares of the company’s stock valued at $196,000 after acquiring an additional 69,758 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in KORU Medical Systems by 189.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock valued at $617,000 after purchasing an additional 158,914 shares during the last quarter. Jane Street Group LLC lifted its stake in KORU Medical Systems by 136.7% in the 1st quarter. Jane Street Group LLC now owns 163,137 shares of the company’s stock valued at $414,000 after purchasing an additional 94,214 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in KORU Medical Systems in the 1st quarter valued at about $63,000. Finally, Geode Capital Management LLC lifted its stake in KORU Medical Systems by 101.3% in the 2nd quarter. Geode Capital Management LLC now owns 997,147 shares of the company’s stock valued at $3,571,000 after purchasing an additional 501,875 shares during the last quarter. Institutional investors own 58.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on KRMD shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $6.00 price objective on shares of KORU Medical Systems in a report on Friday, March 13th. B. Riley Financial upped their price objective on KORU Medical Systems from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Wall Street Zen downgraded KORU Medical Systems from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KORU Medical Systems in a report on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.25.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.